FDA approves Pfizer NDA review for rheumatoid arthritis drug
Tofacitinib an investigational drug is an oral JAK inhibitor. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012 for the
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.